8M€ B-Round for AMAL Therapeutics

8M€ B-Round for AMAL Therapeutics

Swiss cancer vaccine developer AMAL Therapeutics has raised €8m in a Series B round. Along with the lead investors, Boehringer Ingelheim Venture Fund (BIVF), BioMedPartners and Helsinn Investment Fund,  also two of the three lead investors of Amal’s CHF3m Series A financing, VI Partners and High-Tech Gründerfonds (the third was BIVF), as well as Schroder Adveq participated in the financing round. The proceeds will be used for clinical development of lead candidate ATP128 for colorectal cancer through to clinical proof-of-concept.

More

Leave a reply